Board Meeting13 May 2026, 01:05 pm
Onesource Pharma Approves FY26 Standalone & Consolidated Results
AI Summary
Onesource Specialty Pharma Ltd's board approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026, in its meeting held on May 13, 2026. The board also approved the appointment of B S R & Co LLP as the statutory auditors for a term of five years, replacing Deloitte Haskins & Sells. An unmodified opinion was issued in the Auditors’ Report for the financial year ended March 31, 2026.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- B S R & Co LLP appointed as statutory auditors for five years.
- Deloitte Haskins & Sells' term as statutory auditors ends.
- Unmodified opinion issued in the Auditors’ Report for FY26.
Price Impact
More from ONESOURCE